Trial Profile

Effect of olmesartan medoxomil on the progression of coronary atherosclerosis in patients with stable angina pectoris

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Sep 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olmesartan medoxomil (Primary)
Indications Angina pectoris; Atherosclerosis; Coronary artery disease
Focus Biomarker; Pharmacodynamics; Therapeutic Use
Acronyms OLIVUS; OLIVUS-Ex

Most Recent Events

01 Jul 2012 New source identified and integrated (University Hospital Medical Information Network - Japan UMIN000008309).
01 Jul 2012 Actual initiation date (Jun 2012) as reported by University Hospital Medical Information Network - Japan.
01 Jan 2012 Extension study results published in Atherosclerosis.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com